Health Care / Medicine

The Federal Trade Commission has sued CVS Caremark, Express Scripts and Optum Rx, alleging that they engage in 'anticompetitive and unfair rebating practices' as it relates to insulin. One legal expert believes the FTC might win this legal battle.

Following a months-long dispute, data platform Particle Health filed an antitrust lawsuit against Epic, alleging that the EHR giant is using its dominance in the market to prevent competition in the payer platform space. Particle believes the lawsuit is an ‘unprecedented challenge’ to Epic’s market power, while Epic thinks the startup’s claims are ‘baseless.’

In two letters, U.S. representatives and senators called for an extension of the enhanced premium tax credits, which are set to expire in 2025 and have lowered costs for those purchasing coverage on the marketplace.

During a panel discussion at MedCity News’ INVEST Digital Health conference, three healthcare leaders shared their expert insight on what needs to change in order to improve the industry’s cybersecurity strategy.

The current model of siloed, proprietary development is failing us. It's slow, expensive, and often results in technologies that never see the light of day. What if, instead, we embraced an open-source approach to medical device innovation?

Three-quarters of U.S. providers and payers say they have increased their IT spending over the past year, according to a new report from Bain & Company and KLAS Research. Both providers and payers are investing in cybersecurity technology, as well as AI tools.

Securities regulators say the role of Ipsen employee Dishant Gupta made him privy to details of the Epizyme acquisition. Gupta allegedly accumulated Epizyme shares while the deal was negotiated, then sold all of them hours after the transaction was announced.

Kamala Harris and Donald Trump have largely different healthcare policies. However, there are some areas where they have similarities, like healthcare costs.

More than 330 provider organizations signed letters this week urging the White House and Congress to extend a pandemic-era telehealth prescribing flexibility. Failure to extend this policy would cause millions of Americans to lose access to treatment, they argued.

The AMA came out in support of the Biden-Harris Administration's final rule on mental health parity, while AHIP and the Blue Cross Blue Shield Association argue that it will increase costs and negatively affect access to care.

The European Union’s highest court sided with Illumina, agreeing that the European Commission had no authority to review the acquisition of liquid biopsy company Grail. The ruling comes after Illumina stopped challenging antitrust litigation, opting to instead spin out Grail as a standalone company.

A federal judge recently blocked the FTC's ban on noncompetes. The decision has important implications for healthcare.

Aetna will begin covering intrauterine insemination. It is the first major insurer to update this coverage policy nationwide, the payer claimed.

Johnson & Johnson announced last week a major change in the way it offers 340B pricing for two medications. The change is "inconsistent" with the 340B statute, according to HRSA.

The industry is increasingly under attack by lawmakers from both parties for drug prices most Americans regard as unreasonable, so the election outcome could be pivotal to drug companies’ fortunes.

The law amends the state’s ‘certificate of need’ system, which allows existing hospitals and other health facilities to block would-be competitors’ plans to expand by arguing there’s insufficient need for their services.

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.

The White House might soon finalize a rule that will either save or cost patients billions of dollars in prescription drug costs. The rule concerns ‘copay accumulators,’ which are programs health plans use to prevent copay assistance from counting toward patients’ deductibles or out-of-pocket maximums.

More than 700 hospitals across the rural U.S. are at risk of closing due to their financial woes — and for more than half of these hospitals, the risk of closure is immediate, according to a new report. The report argued this is due largely to inadequate reimbursement from health plans.

Recent financing news includes several companies raising money to advance their research to the clinic. Here’s a look back at funding rounds from companies such as Outpace Bio, GRO Biosciences, and Confo Therapeutics.